Nihar Ranjan Das

Dr. Nihar Ranjan Das


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Current Neurovascular Research
Verified
Journal Article
Closed access
PDF file
NDNihar Ranjan Das
Nihar Ranjan Das
BVBhupesh Vaidya
Bhupesh Vaidya
PKPragyanshu Khare
Pragyanshu Khare
MBMahendra Bishnoi
Mahendra Bishnoi
SSShyam Sunder Sharma
Shyam Sunder Sharma
Background: PPAR gamma co-activator 1α (PGC-1α) is known as the master regulator of mitochondrial biogenesis. It is also a co-activator of peroxisome proliferator-activated receptor-gamma (PPARγ) and plays a role in preventing mitochondrial dysfunction in several neurodegenerative disorders, including Parkinson’s disease (PD). Depletion in the levels of these proteins has been linked to oxidative stress, inflammation, and DNA damage, all of which are known to contribute to the pathogenesis of PD. Objective: In the present study, combination therapy of PPARγ agonist (GW1929) and PGC-1α activator (alpha-lipoic acid) was employed to ameliorate cognitive deficits, oxidative stress, and inflammation associated with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. Results: Our study showed that MPTP-induced PD rats exhibited an increase in oxidative stress and inflammation, leading to cognitive deficits. Furthermore, MPTP-induced PD rats also exhibited reduced mitochondrial biogenesis in comparison to control and sham animals. Intraperitoneal administration of GW 1929 and alpha-lipoic acid in doses lower than those earlier reported individually in literature led to an improvement in the cognitive deficits in comparison to MPTP-induced PD rats. These improvements were accompanied by a reduction in the levels of oxidative stress and inflammation. In addition, an increase in mitochondrial biogenesis was also observed after the combination of these pharmacological agents. Conclusion: Our results provide a rationale for the development of agents targeting PPARγ and PGC-1α as potent therapeutics for the treatment of neurological diseases like PD.



12 August 2025 in Journal of Biomaterials Applications
Verified
Journal Article
Closed access
SMSonali Mandal
Sonali Mandal
NDNihar Ranjan Das
Nihar Ranjan Das
KMKaushik Mukherjee
Kaushik Mukherjee
TGTapan Kumar Giri
Tapan Kumar Giri
One of the disadvantages of traditional ophthalmic formulations is their short residence time in the eye. An in situ gel is recommended as a remedy, as it can be converted into a gel upon contact with the eye and adhere for an extended period. Tamarind seed polysaccharide (TSP) is non thermo-sensitive and possesses the necessary properties to be used as a vehicle for administering medication to the eye. However, the administration of medication into the eyes through TSP based in situ gel has not yet been studied. N -isopropyl acrylamide was grafted onto TSP to make it temperature sensitive. Then, a TSP-based thermo-sensitive in situ gel-forming solution loaded with dorzolamide hydrochloride (2% w/v) was developed and evaluated through in vitro , ex vivo , and in vivo tests. The in situ gel forming solution turns into a gel at 37°C. The safety and efficacy of the formulation were confirmed through an in vivo study on rabbit eyes with induced glaucoma. The findings indicate that the in situ gel significantly reduced intraocular pressure (IOP), with effects comparable to those of marketed eye drops.

4 May 2026 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
RNRakesh Kumar Nayak
Rakesh Kumar Nayak
SMSoumya Ranjan Mohapatra
Soumya Ranjan Mohapatra
SSSatyam Kumar Sahoo
Satyam Kumar Sahoo
SSSusanta Kumar Sahu
Susanta Kumar Sahu
BCBimalendu Chowdhury
Bimalendu Chowdhury
NDNihar Ranjan Das
Nihar Ranjan Das
Human microbiota consists of trillions of microbial cells dominated by bacteria, which live in the human body, while the term microbiome refers to the collective genetic material of microorganisms. Among them, the gut microbiota has emerged as pivotal, producing its own metabolites, neurotransmitter precursors, and immune mediators that affect brain development and function. These signals function via the complex, bidirectional Gut–Brain Axis (GBA). This is a communication network that connects the gastrointestinal tract to the central nervous system. This axis plays an important role in the regulation of gastrointestinal homeostasis, neurodevelopment, emotional regulation, and cognitive processes. Increasing evidence suggests that microbial dysbiosis within the gastrointestinal tract is involved in the pathogenesis and progression of several neurological and neurodegenerative disorders, including mood disorders, schizophrenia, autism spectrum disorder, Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Huntington’s Disease. These insights have opened new therapeutic possibilities, and multiple microbiota-targeted interventions, such as dietary modification, prebiotics, probiotics, postbiotics, psychobiotics, antibiotics, and Fecal Microbiota Transplantation (FMT), are now being explored for their therapeutic value, especially in Alzheimer’s disease.

24 November 2025 in ACS Omega
Verified
Journal Article
Open access
APAshish Panigrahi
Ashish Panigrahi
NDNihar Ranjan Das
Nihar Ranjan Das
NYNeha Yadav
Neha Yadav
SPSwarupa Panda
Swarupa Panda
ASAbinashi Sabyasachi Sethy
Abinashi Sabyasachi Sethy
VTVivek Tiwari
Vivek Tiwari
Adequate cerebral oxygenation is vital for neonatal survival and the establishment of a healthy brain function. A disruption in this critical balance, particularly during the perinatal period, can result in hypoxic-ischemic encephalopathy (HIE)a severe and potentially fatal form of neonatal brain injury caused by diminished oxygen and blood flow to the brain. HIE is a major contributor to neonatal morbidity and mortality worldwide, with an even greater burden in low-resource settings, where delays in diagnosis and limited access to timely intervention exacerbate long-term neurodevelopmental outcomes. Affected neonates frequently suffer from a spectrum of sequelae, including cerebral palsy, epilepsy, intellectual disability, and other persistent neurological impairments. Currently, therapeutic hypothermia (TH) is the standard-of-care neuroprotective intervention for moderate to severe HIE. However, its efficacy is highly time-dependent and constrained by the critical need for early and accurate diagnosis often within the first 6 h of life. Traditional diagnostic modalities, including clinical assessment, serum protein biomarkers, electroencephalography (EEG), and neuroimaging, frequently lack the sensitivity and specificity required for early risk stratification, thereby limiting their clinical utility during this narrow therapeutic window. In this context, metabolomics-based approaches have emerged as powerful tools to detect subtle early biochemical changes associated with neuronal injury and energy failure. Biomarkers such as lactate, glutamate, succinate, S-100 protein, and CK-BB have shown potential in reflecting metabolic disturbances characteristic of the HIE. Recent advances in nuclear magnetic resonance (NMR) spectroscopy, when integrated with artificial intelligence (AI)-based pattern recognition algorithms, have further enabled the identification of complex metabolic signatures that are both disease-specific and prognostically informative. Despite their promise, the clinical translation of metabolomics-derived biomarkers remains limited by significant preanalytical variability, particularly in sample handling, processing, and storage conditions. Factors such as anticoagulant type, temperature fluctuations, and delays in sample processing can profoundly alter metabolite stability, leading to inconsistent results and reduced reproducibility across cohorts. To address these limitations, this review highlights common pitfalls in blood-based metabolomics workflows and presents a novel, rigorously standardized, multipanel metabolomics strategy for HIE evaluation. By coupling high-resolution NMR spectroscopy with machine learning techniques, we propose the development of a composite “Metabolic Index of Brain Health” that quantitatively captures the extent and severity of hypoxic-ischemic injury. This approach not only enhances diagnostic precision but also enables early risk stratification, paving the way for timely therapeutic interventions.